The U.S. Meals and Drug Administration (FDA) has granted breakthrough remedy designation to ficerafusp alfa together with Keytruda (pembrolizumab) for the primary...
The U.S. Meals and Drug Administration (FDA) has accredited Inluriyo (imlunestrant) for the therapy of adults with estrogen receptor (ER)-positive and HER2-negative...
The U.S. Meals and Drug Administration lately accepted Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) for subcutaneous use in adults and pediatric sufferers...
